Clinical Trial

A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 12-week follow-up period.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-05-23
Trial Details
NCT Number NCT07311226
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Healthy Participants
Enrollment 32 participants
Start Date 2025-12-31
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22